PARSIPPANY, N.J., Sept. 17, 2024 /PRNewswire/ — Zoetis Inc., the world’s leading animal health company, is set to unveil its new hematology analyzer Vetscan OptiCell™, a cartridge-based, AI-powered diagnostic tool that provides advanced Complete Blood Count (CBC) analysis. The analyzer – to be introduced to the U.S. market later this year – represents a significant leap in technology and offers meaningful time, cost and space savings for veterinary care teams, to enable better patient outcomes and allows for a more efficient clinic workflow.
Vetscan OptiCell reaffirms Zoetis’ longstanding commitment to advancing veterinary medicine through meaningful innovation. The latest addition to Zoetis’ suite of diagnostic products and services offers an advanced approach to hematology by utilizing cell-focusing and AI-powered classification technology for CBC analysis, delivering reference lab quality accuracy1 at the point of care.
Abhay Nayak, President of Global Diagnostics at Zoetis said, “This latest innovation further strengthens our hematology story, particularly when partnered with Vetscan Imagyst® AI Blood Smear – reinforcing the existing capabilities of Zoetis’ Virtual Laboratory portfolio, providing a comprehensive and connected platform.”
Dr. Richard Goldstein, DVM, DACVIM, DECVIM-CA, Global Chief Medical Officer and Head of Medical Affairs at Zoetis shared: “Vetscan OptiCell delivers high-quality results, enables improved efficiency, and provides a compact footprint. For the first time, we are able to use advanced AI image recognition technology to characterize the blood cells instead of relying on their size or other physical parameters. This is an important step forward for our hematology story, demonstrating Zoetis’ devotion to the well-being of animals and those that care for them.”
The innovative cartridge-based solution joins Vetscan® HM5 as the second Zoetis Diagnostics hematology analyzer available to customers, further expanding the in-clinic capability to count and characterize blood cells. Combined with the pioneering AI-powered Vetscan Imagyst analyzer, the state-of-the-art suite of products and services characterizes the future of veterinary diagnostics.
The first public viewing of the new analyzer will be at the internationally attended London Vet Show, booth N50, ExCel London, UK, 14-15 November 2024. Pre-orders will be available for customers in the US in late 2024.The analyzer will also be presented to North American customers at VMX in Orlando, January 2025.
Supported by the Virtual Laboratory’s integrated network of board-certified specialists, this portfolio provides world-leading pathology expertise at the fingertips of veterinarians and delivers deep insights to elevate patient care.
To schedule an interview, please contact Garnett Keeler PR.
For more information about OptiCell, visit https://www.zoetisdiagnostics.com/opticell
About Zoetis
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers and ranchers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $8.5 billion in 2023 with approximately 14,100 employees. For more information, visit www.zoetis.com.
Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to: business plans or prospects, future operating or financial performance, future guidance, future operating models; disruptions in our global supply chain; R&D costs; timing and likelihood of success; expectations regarding products, product approvals or products under development, expected timing of product launches; expectations regarding the performance of acquired companies and our ability to integrate new businesses; expectations regarding the financial impact of acquisitions; future use of cash, dividend payments and share repurchases; tax rate and tax regimes and any changes thereto; and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management’s underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.
References
1. Data on file, Study No. DHXMZ-US-24-235, Zoetis Inc.
All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. © 2024 Zoetis Services LLC. All rights reserved. VTS-01509
Photo – https://healthtechnologynet.com/wp-content/uploads/2024/09/Zoetis_Vetscan_OptiCell.jpg
SOURCE Zoetis
Young Women Activists Launch "What Girls Want," Demand World Leaders Put Girls at the Center…
As a leader in neuroscience, Teva is committed to researching new treatment innovations that may…
As a leader in neuroscience, Teva remains committed to helping address unmet needs in the…
Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment…
MIAMI, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Smart for Life, Inc. (OTC: SMFL) (“Smart for…
SAN FRANCISCO, Sept. 20, 2024 /PRNewswire/ -- The Global Ultrasound Institute (GUSI) is proud to…